Icatibant

HOE 140, JE 049, JE049

    This is a preview of subscription content, log in to check access.

    Table I
    Table II

    References

    1. 1.

      Profiles of participating companies. BIO 2004: Annual International Convention. Business Forum: 6 Jun 2004

      Google Scholar 

    2. 2.

      Jerini AG. Jerini Concludes its Icatibant Phase II Study in Hereditary Angioedema with Positive Results. Media Release: 26 Aug 2004. Available from URL: http://www.jerini.com

      Google Scholar 

    3. 3.

      Jerini AG. Jerini Initiates Pivotal Registration Study for Icatibant in Hereditary Angioedema. Media Release: 8 Sep 2004. Available from URL: http://www.jerini.com

      Google Scholar 

    4. 4.

      Jerini AG. Jerini Receives FDA Fast Track Designation for Icatibant in Hereditary Angioedema. Media Release: 22 Jul 2004. Available from URL: http://www.jerini.com

      Google Scholar 

    5. 5.

      Jerini. Jerini Has Been Granted Orphan Drug Designation by U.S. FDA for Icatibant, JE049, to Treat Patients with Angioedema. Media Release: 18 Nov 2003. Available from URL: http://www.jerini.com

      Google Scholar 

    6. 6.

      Proud D. Clinical application of kinin antagonists. Canadian Journal of Physiology and Pharmacology 72 (Suppl. 2): 19, 1994

      Google Scholar 

    7. 7.

      Jerini. Jerini Announces Positive Results in a Subcutaneous Bioavailability Study for Icatibant. Media Release: 14 Apr 2004. Available from URL: http://www.jerini.com

      Google Scholar 

    8. 8.

      Wirth KJ, Gehring D, Schölkens BA. Effect of Hoe 140 on bradykinin-induced bronchoconstriction in anesthetized guinea pigs. American Review of Respiratory Disease 148: 702–706, Sep 1993

      PubMed  Article  CAS  Google Scholar 

    9. 9.

      Wirth KJ, Gehring D, Schölkens BA. Effect of HOE 140 on bradykinin-induced bronchoconstriction in anaesthetised guinea pigs. Naunyn-Schmiedeberg’s Archives of Pharmacology 344 (Suppl. 2): R141, 1991

      Google Scholar 

    10. 10.

      Jerini. Jerini’s Bradykinin Antagonist Icatibant Shows Promise in Treatment of Refractory Ascites in Liver Cirrhosis in a Phase II Study. Media Release: 2 Dec 2003. Available from URL: http://www.jerini.com

      Google Scholar 

    11. 11.

      Sun W, Wainwright CL. The potential antiarrhythmic effects of exogenous and endogenous bradykinin in the ischaemic rat heart in vivo. Coronary Artery Disease 5: 541–550, Jun 1994

      PubMed  CAS  Google Scholar 

    12. 12.

      Gaudron P, Hu K, Zdrojewski T, et al. AT1-receptor blocker versus angiotensin converting enzyme inhibitor in acute myocardial Role of dosage and bradykinin on remodelling, hemodynamics and mortality in the rat model. Journal of the American College of Cardiology 31 (Suppl. 2A): 311, Feb 1998

      Article  Google Scholar 

    13. 13.

      Proud D, Reynolds CJ, Broomfield J. Bradykinin effects in guinea pig tracheal epithelial cells are mediated through a gB2 kinin receptor and can be inhibited by the selective antagonist Hoe 140. Journal of Pharmacology and Experimental Therapeutics 264: 1124–1131, Mar 1993

      PubMed  CAS  Google Scholar 

    14. 14.

      Hock FJ, Wirth K, Albus U. Hoe 140, a new potent and long acting bradykinin-antagonist: in vitro studies. British Journal of Pharmacology 102: 769–773, Mar 1991

      PubMed  Article  CAS  Google Scholar 

    15. 15.

      Rhaleb N-E, Rouissi N, Jukic D. Pharmacological characterization of a new highly potent ß2 receptor antagonist (HOE 140: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin). European Journal of Pharmacology 210: 115–120, 14 Jan 1992

      PubMed  Article  CAS  Google Scholar 

    16. 16.

      Félétou M, Germain M, Thurieau C. Agonistic and antagonistic properties of the bradykinin ß2 receptor antagonist, Hoe 140, in isolated blood vessels from different species. British Journal of Pharmacology 112: 683–689, Jun 1994

      PubMed  Article  Google Scholar 

    17. 17.

      Sakamoto T, Sun J, Barnes PJ, et al. Effect of a bradykinin receptor antagonist, HOE 140, against bradykinin- and vagal stimulation-induced airway responses in the guinea-pig. European Journal of Pharmacology 251: 137–142, 14 Jan 1994

      PubMed  Article  CAS  Google Scholar 

    18. 18.

      Sakamoto T, Elwood W, Barnes PJ. Evaluation of a bradykinin antagonist (HOE 140) against bradykinin and platelet activating factor induced airway responses in the guinea pig. Thorax 47: 241P, Mar 1992

      Google Scholar 

    19. 19.

      Sakamoto T, Elwood W, Barnes PJ, et al. Effect of Hoe 140, a new bradykinin receptor antagonist, on bradykinin- and platelet- activating factor-induced bronchoconstriction and airway microvascular leakage in guinea pig. European Journal of Pharmacology 213: 367–373, 31 Mar 1992

      PubMed  Article  CAS  Google Scholar 

    20. 20.

      Sakamoto T, Elwood W, Barnes PJ. Effect of a novel bradykinin antagonist (HOE140) against bradykinin, platelet activating factor, sodium metabisulfite and allergen induced airway responses in the guinea pig. American Review of Respiratory Disease 145: A859, Apr 1992

      Google Scholar 

    21. 21.

      Wirth K, Hock FJ, Albus U. Hoe 140, a new potent and long acting bradykinin-antagonist: in vivo studies. British Journal of Pharmacology 102: 774–777, Mar 1991

      PubMed  Article  CAS  Google Scholar 

    22. 22.

      Damas J, Remacle-Volon G. Influence of a long-acting bradykinin antagonist, Hoe 140, on some acute inflammatory reactions in the rat. European Journal of Pharmacology 211: 81–86, 28 Jan 1992

      PubMed  Article  CAS  Google Scholar 

    23. 23.

      Featherstone RL, Parry JE, Church MK. The effects of kinin antagonism with HOE 140 on the response of guinea-pigs to allergen. Clinical and Experimental Allergy 23 (Suppl. 1): 32, Feb 1993

      Google Scholar 

    24. 24.

      Austin CE, Foreman JC, Scadding GK. Reduction by Hoe 140, the B2 kinin receptor antagonist, of antigen-induced nasal blockage. British Journal of Pharmacology 111: 969–971, Apr 1994

      PubMed  Article  CAS  Google Scholar 

    25. 25.

      Jerini AG. Jerini Announces Positive Phase II Study Results with Icatibant for the Treatment of Hereditary Angioedema. Media Release: 13 Jan 2004. Available from: URL: http:// www.jerini.com

      Google Scholar 

    26. 26.

      Avery J, Barber C. A topical bradykinin antagonist first clinical trial of icatibant nasal spray in seasonal allergic rhinitis. Allergy and Clinical Immunology News (Suppl. 2): 415, 1994

      Google Scholar 

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Icatibant. Drugs R D 5, 343–348 (2004). https://doi.org/10.2165/00126839-200405060-00006

    Download citation

    Keywords

    • Bradykinin
    • Angioedema
    • Quinapril
    • Hereditary Angioedema
    • Orphan Drug Status